Definium Therapeutics, Inc.: 10-Q filed 2025-05-08
What Definium Therapeutics, Inc. reported in its quarterly report filed 2025-05-08 (fiscal Q1 2025): 34 published measures, 70 facts as tagged in accession 0000950170-25-066387.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-05-08
- Fiscal period
- fiscal Q1 2025
- Accession
- 0000950170-25-066387 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Definium Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 275,323,000 | USD | |
| At 2024-12-31 | 302,151,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 52,517,000 | USD | |
| At 2024-12-31 | 60,703,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 222,806,000 | USD | |
| At 2024-12-31 | 241,448,000 | USD | |
| At 2024-03-31 | 196,059,000 | USD | |
| At 2023-12-31 | 78,134,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 82,854,000 | USD | |
| At 2024-12-31 | 273,741,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -23,348,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -54,400,000 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -29,419,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -16,598,000 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1,002,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 169,247,000 | USD | 91 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -162,458,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 0 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | -422,227,000 | USD | |
| At 2024-12-31 | -398,879,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 85,067,855 | shares | 90 |
| 2024-01-01 to 2024-03-31 | 47,860,757 | shares | 91 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 87,091,461 | shares | 90 |
| 2024-01-01 to 2024-03-31 | 47,860,757 | shares | 91 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -0.27 | USD/shares | 90 |
| 2024-01-01 to 2024-03-31 | -1.14 | USD/shares | 91 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -0.35 | USD/shares | 90 |
| 2024-01-01 to 2024-03-31 | -1.14 | USD/shares | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -32,159,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -22,204,000 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 221,700,000 | USD | |
| At 2024-12-31 | 281,620,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 602,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 434,000 | USD | 91 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 30,481,000 | USD | |
| At 2024-12-31 | 38,849,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 2,268,000 | USD | |
| At 2024-12-31 | 2,010,000 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 19,918,000 | USD | |
| At 2024-12-31 | 19,918,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 32,159,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 22,204,000 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 23,357,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 11,705,000 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 75,511,375 | shares | |
| At 2024-12-31 | 75,100,763 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 802,000 | USD | |
| At 2024-12-31 | 819,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 606,000 | USD | |
| At 2024-12-31 | 613,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 11,497,000 | USD | |
| At 2024-12-31 | 12,829,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 9,259,000 | USD | |
| At 2024-12-31 | 7,879,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -23,348,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -54,400,000 | USD | 91 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -23,365,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -53,907,000 | USD | 91 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -23,348,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -54,400,000 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 8,802,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 10,499,000 | USD | 91 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 0 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 527,000 | USD | 91 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 8,811,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -32,196,000 | USD | 91 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 602,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 434,000 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 258,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 1,509,000 | USD | 91 |
Inspect the source
- Entity
- Definium Therapeutics, Inc. / CIK 0001813814
- Captured
- 2026-09-21T17:28:26.473Z
- SEC response SHA-256
afb07c3c9dec92bfe71c8ab2ba2df1270af37378dc83d500c5a8b4b1146df0ab
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001813814.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))